Objectives Irritable bowel syndrome is often treated in primary-care settings, and it has a relatively large economic impact. Cognitive behaviour therapy (CBT) in addition to mebeverine has been shown to be effective in the short term, compared with treatment with mebeverine alone. This study assesses the impact that CBT in addition to mebeverine has on resource use, and its costeffectiveness.
Introduction
Irritable bowel syndrome (IBS) affects approximately 10 -15% of the population, but many people do not seek treatment [1] . The condition is characterized by abdominal pain, altered bowel habit, abdominal bloating and reduced quality of life [2, 3] . A number of studies have estimated the economic impact of IBS [1, 4] . In the UK, the cost to the National Health Service of IBS presenting in primary-care settings was estimated to be over £200 million, using 1999 prices and assuming a prevalence rate of 9% [3] . The cost of lost employment adds considerably to these direct-care costs [5] .
Options for treating IBS include pharmacotherapy [6, 7] , psychotherapy [7] , hypnotherapy [8] and cognitive behaviour therapy (CBT) [9, 10] . In addition to establishing the effectiveness of different interventions, it is crucial to assess their cost-effectiveness, given that the supply of healthcare resources is limited. In one of the few economic evaluations in this area, Creed et al. [7] compared psychotherapy, paroxetine and usual care, for patients with severe IBS in secondary care. At the 1-year follow-up, compared with usual care, both psychotherapy and drug therapy improved quality of life and resulted in reduced costs (significantly so for psychotherapy).
Previously, it has been shown that CBT in addition to mebeverine is more effective than mebeverine alone in reducing the symptoms of IBS and the disability due to it, in the short term [11] . The aims of this paper are to (i) compare the service costs and total costs (including lost employment) associated with mebeverine in addition to CBT and with mebeverine alone, at the 3-month, 6-month and 12-month follow-ups and (ii) to compare the cost-effectiveness of the two options. central and south London. Approval was received from St Thomas' Hospital Research Ethics Committee, Guy's Hospital Research Ethics Committee and Barnet, Enfield and Haringey Local Research Ethics Committee. A baseline questionnaire assessment of the potential participants was conducted within 2 weeks, at which time eligibility and Rome I criteria for IBS were assessed (although Rome I criteria did not determine inclusionthis was based on the clinical diagnosis). Patients were excluded if they were pregnant or breast-feeding, had symptoms suggestive of colorectal cancer, had a past or current condition that could complicate the evaluation, had abdominal pain that was relieved by acid-inhibiting medication, were unable to fill in the questionnaires or did not give written consent. Patients subsequently received usual care from their GPs for 2 weeks; if after that time they had moderate or severe symptoms, they were offered 270 mg of mebeverine three times a day for 2 weeks. After 4 weeks, if patients continued to have moderate or severe symptoms, they were randomized by an independent statistician to receive mebeverine alone or mebeverine in addition to CBT. (This was done using random numbers derived in blocks of four from random number tables.) The run-in period on usual care was justified, as mebeverine is currently prescribed by primary-care physicians. Moreover, it was necessary to identify the patients in whom symptoms persisted, which could potentially be addressed by the addition of CBT.
The basic course of CBT consisted of up to six 50-min sessions, and included education about IBS and techniques to reduce focussing on symptoms, manage stress and prevent relapse. It was a collaborative approach in which patients learned new skills and negotiated more adaptive ways of coping. Session 1 included a cognitive behavioural assessment, and defined the problems and goals of treatment. Subsequent sessions consisted of feedback from previous sessions, homework review, homework discussion, goal setting and a 'recap' of key issues. Participants could request further sessions if necessary. It was decided to focus largely on IBS symptoms and associated maladaptive behaviours, because the aim was to enhance self-efficacy, self-care and to improve functioning at the workplace and in social settings. The CBT intervention did not include dietary advice, other than to suggest that patients should have a healthy diet as far as possible. A review by Blanchard [12] has, nevertheless, shown that CBT can have other aims and goals, for example, stress management and participation in activities that were previously avoided.
Patients were assessed at the end of treatment and at 3, 6 and 12 months after treatment ended. Cost-effectiveness analysis requires that costs be linked to a single outcome measure. The primary outcome measure was the score on a symptom-severity scale specific to IBS [13] . This scale has a maximum score of 500, and symptoms can be categorized as normal (score < 75), mild (75 -174), moderate (175-299) or severe (300 -500). The authors of the scale suggest that a change of 50 is clinically significant, and this was used to guide the economic evaluation. Secondary measures included the Hospital Anxiety and Depression Scale [14] and the Work and Social Adjustment Scale [15] .
Service use
Services used in the 3 months prior to the baseline assessment, and during the 3-month, 6-month and 12month periods after treatment ended, were measured with the Client Service Receipt Inventory [16] . This schedule, developed in the 1980s and used in numerous evaluations of healthcare and social-care interventions, enables contact with a comprehensive range of services to be measured over a specific period of time, as a precursor to generating service costs. (In this study, service use during the immediate treatment phase, other than medication and therapy, was not measured; however, it was measured in the follow-up period). The intention was to measure service use comprehensively (i.e. to include all services that might be affected by the interventions). Services included those provided by healthcare and social-care agencies. Informal care (i.e. unpaid help) provided by family/friends was not included. Patients were asked for details regarding the number of contacts with specific services; wherever it was relevant, they were asked for the average duration of contact. The number of CBT sessions was centrally recorded.
Service costs
Unit costs were generally obtained from a recognized source [17] , and attached to the service-use data. Some unit costs were not available, and best estimates were made. The cost of CBT was measured, by multiplying the number of sessions received by the unit cost of CBT. The therapy was delivered by practice nurses, who had a unit cost of £31 per hour of patient contact [17] . This figure includes qualifications, capital costs and overheads, as well as salary. The nurse therapists attended a 12-day initiation course, and the estimated cost of this was £3000 per nurse (including nurse time and trainer time). Nurses received weekly supervision while delivering therapy, at an estimated cost of £51 per hour (nurse time and supervisor time). These costs were divided by the number of CBT sessions each nurse delivered as part of the study. Mebeverine hydrochloride, or training required to deliver it, was not costed, as patients in both arms of the trial received the drug, and it was therefore costneutral.
Lost employment costs
Lost-employment costs were calculated by measuring the number of days lost from work during the 3 months (for any health problems) preceding each interview. The average daily wage (sex-specific) was calculated from national data [18] and multiplied by the number of lost workdays. Not all work time is productive and, following suggestions made by Pritchard and Sculpher, the wage costs were adjusted downwards, using a multiplier of 0.8 [19] . Non-employment-related indirect costs were not estimated, and no account was taken of reduced productivity at work that did not result in lost workdays.
Analysis
Mean total cost differences were tested for significance, using regression analysis with the randomization group being used as the sole independent variable. The regression model was bootstrapped using 10 000 repetitions, so that appropriate confidence intervals could be obtained in the presence of potentially skewed data distributions that are common in economic evaluations. Bootstrapping methods make no assumptions about the distribution of the statistics of interest [20] . Discounting was not conducted, as data collection did not progress beyond 12 months' follow-up.
The cost-effectiveness of CBT in addition to mebeverine, compared with that of drug therapy alone, was assessed using an incremental net-benefit analysis [21] . Such analyses allow us to determine the relationship between treatment costs and unit changes in treatment effectiveness. In this study, we have divided treatment effectiveness by fifty, so as to examine the cost of achieving a clinically important change in outcome [13] . Net benefit (NB) is defined as
where E = effectiveness (change in symptom-severity scale score, divided by 50), l = the monetary value placed on the change in effectiveness and SC = service costs. A net benefit occurs if the monetary value of the effectiveness exceeds the cost incurred to produce that change. The value of a clinically important unit change in effectiveness (l) is, however, unknown; hence, a range of values was used (£0 -500, in increments of £100). Incremental net benefit is estimated by comparing the net benefits for each group for each of the different values of l. This was performed using regression analysis, with net benefit being used as the dependent variable and the group indicator as the sole independent variable. A total of 1000 resamples of the group coefficient were obtained using bootstrapping, and the proportion of these that were above zero indicated the probability that CBT in addition to mebeverine was the most cost-effective option. These probability values were used to produce cost-effectiveness acceptability curves for each of the follow-up periods [22] . Sensitivity analyses were then performed on the net-benefit statistics, by reducing and increasing the cost of therapy by 25%.
In the clinical-outcomes paper [11] , missing values for the overall symptom-severity score were imputed from individual items that made up that score, if at least 75% of these items were available. These imputed scores were also used in the net-benefit analysis described above. Imputed values were, however, only used in place of missing clinical data, not cost data. This did not cause problems, as the subsequent cost-effectiveness analysis focussed on therapy costs, which were complete. An intention-to-treat approach was used, by which cost and net-benefit comparisons were made, even if the patients in the CBT in addition to mebeverine group dropped out of therapy (including those with zero contacts).
Results
Out of a total of 334 patients, 245 eligible patients had been referred to the study. At the third assessment, 148 patients had IBS of sufficient severity to warrant randomization to drug therapy alone or to CBT in addition to mebeverine, and had valid data for the analyses in this paper. The mean (SD) age in the drug and in the CBT in addition to mebeverine groups were 33.4 (8.4) and 33.8 (9.7) years, respectively. The majority of patients were women; nearly half had suffered from IBS for at least 5 years, and a large proportion had a family history of the condition ( Table 1 ). The vast majority of patients also met the Rome I criteria for IBS. The groups had similar baseline demographic characteristics and clinical scores, with no statistically significant differences at the 95% level of confidence. 90% confidence intervals did, however, indicate differences in the Hospital Anxiety and Depression Scale total score and anxiety score. Each follow-up measure of symptom severity was less than at baseline: this reduction was significantly greater for the CBT in addition to mebeverine group immediately following, and 3 months after, the end of treatment (P < 0.001). The differences in symptom severity were not statistically significant at the 6-month and 12-month follow-ups [11] .
The number (percentage) of participants, randomized to CBT in addition to mebeverine, attending different numbers of sessions is shown in Table 2 . No significant differences were observed between patients who had completed at least six sessions of CBT and those who did not, in terms of age, sex, baseline symptoms, baseline work and social adjustment and baseline depression and anxiety. The mean (SD) cost of CBT was £308 (£202). Kennedy et al. [11] report that 41% of participants either declined therapy or dropped out before it ended. This was mainly due to time commitments. Tables 3 and 4 show the number of participants with resource-use data, the quantity of resources used and their costs during the 3 months preceding the baseline assessment and the follow-up interviews. Few substantial differences were observed between the CBT in addition to mebeverine and the drug therapy groups, in the use of or the cost of any services, or for lost employment at any time period. Substantial variation was, however, recorded in some costs -such as those for mental-health professionalswhich was largely due to the low numbers of patients using them, with some of those who did having a high number of contacts. At baseline, the majority of patients were in contact with their GPs and there was a relatively high level of use of practice nurses. About half of the CBT, cognitive behaviour therapy. sample patients had taken time off from work, owing to health problems. A reduction was observed in the use of both GPs and practice nurses, in the 3 months after the end of treatment; this reduction was maintained during the subsequent follow-up periods. No evidence showed that CBT in addition to mebeverine resulted in a change in the proportion of patients using specific services and therapy had no demonstrable impact on the proportion reporting lost employment. The highest service costs were for GP contacts, non-gastroenterology outpatient appointments, inpatient care and for contacts with mental-health professionals. Lost employment accounted for between 34 and 71% of the total costs. Aggregate service costs and total costs (including lost employment) did differ between the groups and change over time; however, these differences were not statistically significant. (Table 4 shows 95% confidence intervals, but it should be noted that there were no significant differences at the P < 0.1 level of significance).
At the follow-up after treatment, the CBT in addition to mebeverine group had a reduction in severity that was 69 points higher than in the drug group. This equates to 1.4 units of a clinically significant change (69 divided by 50). Dividing the incremental cost (£308) by this difference gives an incremental cost-effectiveness ratio of £220 (i.e. it costs £220 for CBT in addition to mebeverine to achieve a reduction in severity that is 50 points higher than for mebeverine alone). The symptom-change scores also favoured CBT in addition to mebeverine at the 3-month (1.8 units of clinically significant change), 6-month (0.3 units) and 12-month follow-ups (0.1 units). These differences result in incremental cost-effective-ness ratios of £171, £1027 and £3080, respectively. (These are each based on the treatment cost, and on the cumulative outcome achieved before each follow-up.) Although not used in the cost-effectiveness analysis, CBT in addition to mebeverine also resulted in a significant reduction in the work and social-adjustment scale; this was maintained 12 months after treatment [11] . A significant reduction was observed in the Hospital Anxiety and Depression Scale after 12 months, associated with CBT in addition to mebeverine. This, however, was not apparent at each intermediate follow-up point.
The probability that CBT in addition to mebeverine is more cost-effective than drug therapy alone at each follow-up point, for various values placed on a clinically significant change, is shown in Fig. 1 . It can be seen that the relative cost-effectiveness of CBT in addition to mebeverine is greatest during the 3-month follow-up period: it is less cost-effective if outcomes are just measured at the end of treatment. If CBT in addition to mebeverine is to have more than a 50% probability of being the most cost-effective option, the value placed on a clinically important reduction in symptoms would need to be somewhere between £200 and £250. In the longer term, there is only a low probability that CBT in addition to mebeverine is the most cost-effective option.
The impact of applying higher and lower therapy costs on the cost-effectiveness acceptability curves is shown in Fig. 2 . For clarity, we only show the impact of reducing therapy costs on the lowest curve (representing costeffectiveness over 12 months), and of increasing therapy costs on the highest curve (representing cost-effective- ness measured at 3 months after the end of treatment). It can be seen that whereas the probability of CBT in addition to mebeverine being more cost-effective than drug therapy alone is reduced if therapy is more expensive, high probabilities are nonetheless attained as the value placed on a clinically important outcome increases. Conversely, even if therapy costs are reduced, there remain very low probabilities that CBT in addition to mebeverine is the most cost-effective option over 6 or 12 months.
Discussion
Previously, this trial demonstrated that the addition of combined CBT and mebeverine produces favourable outcomes in the short term, but that the effects seem to be reduced after about 6 months. The analyses presented in this paper have shown that such combined treatment does not have any noticeable impact on the use or cost of other services, or on lost employment, after the end of treatment. The absence of an effect on other resources is a common finding in evaluations of interventions in primary-care settings, in which such interventions add slightly to overall costs [23] . Much variation was, nevertheless, observed in the use of some services (for example, mental healthcare) across the sample. We did not conduct analyses of such variations. Elsewhere, however, we have shown that male sex and belief in a physical cause for the symptoms predicted poorer functioning [24] . It is likely that this would translate into an effect on costs (and cost-effectiveness), but this needs to be further investigated. In these analyses, we have compared the average level of cost-effectiveness for each group. Clearly though, cost-effectiveness will differ within groups, and these differences might be due in part to clinical factors such as the level of psychiatric morbidity (which can explain differences in mental healthcare use). If we can identify predictors of outcomes, then we would be able to target the intervention more effectively. Future analyses should address such issues.
Better outcomes were achieved for CBT in addition to mebeverine by the end of treatment and by the 3-month follow-up, but this was at an additional cost of £308. Therefore, it is a value judgement as to whether these improved outcomes are worth the cost. The use of costeffectiveness ratios and cost-effectiveness acceptability curves can inform this judgement by revealing the probability of CBT in addition to mebeverine being seen as being more cost-effective than drug therapy alone, when different values are placed on a clinically important change. The CBT intervention was provided by nurses, and might have been more expensive if provided by psychologists. The latter, however, might not have required the same level of training as nurses, which would affect costs in the other direction. Given the limited supply of psychologists in primary-care settings, it was felt appropriate to use nurses and to base the economic analyses on their costs.
The incremental cost-effectiveness ratios for CBT in addition to mebeverine compared with those for mebeverine alone were lowest for the outcomes measured at the end of treatment and at the 3-month follow-up. The cost-effectiveness acceptability curves revealed that for CBT in addition to mebeverine to be the most costeffective option at the 3-month follow-up, a value of between £200 and £250 would need to be placed on the achievement of a clinically important reduction in symptoms. When outcomes were measured at the 6month and 12-month follow-up, there was only a very low probability that CBT in addition to mebeverine was the most cost-effective option. Therefore, it is clear that combined treatment was most cost-effective in the short term. The sensitivity analyses revealed that it would have a lower probability of being the most cost-effective option if therapy costs were increased by 25%, but that the probability would still exceed 50% if the value placed on a clinically important reduction in symptoms had been between £250 and £300. Even if therapy costs were reduced by 25%, however, there remains a very low probability that CBT in addition to mebeverine would be cost-effective at 6 or 12 months.
Although the focus in these analyses has been on the relationship between changes in symptoms and costs, it should also be noted that CBT in addition to mebeverine resulted in reduced work and social-adjustment problems and, to some extent, in reduced depression and/or anxiety [11] . This reinforces the cost-effectiveness findings presented here.
There are limitations to this study. First, a large number of patients in the CBT in addition to mebeverine group did not attend all the therapy sessions. In primary care, it is common for patients to miss appointments/sessions owing to other commitments, but it does indicate that they will not have received a therapeutic 'dose'. This might have had the effect of reducing the cost-effectiveness of CBT in addition to mebeverine; although, it is also possible that these patients would have improved and at little cost. Second, the 2-week period before the commencement of any treatment might have been insufficient to detect patients in whom symptoms have a relatively long 'cycle time'. Although the run-in period before randomization was 4 weeks, it might have been preferable to have a 4-week period before the assessment, to decide whether to commence mebeverine treatment. Third, we relied on patient self-reports of service use. The accuracy of this method might be questioned. The recall period was, however, relatively short (3 months), and there is no reason to assume that inaccuracies would affect one group more than the other. It is important to recognize that if we wish to obtain a comprehensive record of service use, then patient recall is likely to be the only option, although it might be complemented by the use of administrative records for some services. Previous studies have shown self-report to be an acceptable method of measuring service use [25, 26] . Fourth, service use was measured for the 3-month periods before each interview, but was not measured for the treatment period itself. Clearly, some services, in addition to direct treatment, will have been used during this phase, and the cost of these might have differed between the groups. Fifth, although the costs of work absenteeism were estimated, no attempt was made to calculate the costs of reduced productivity while at work. As such, the productivity costs might be an underestimate. Sixth, informal care provided by family/friends was not included. Elsewhere, it has been shown that informal care is a key cost for chronic fatigue [27] : it might be similarly important for IBS. Seventh, the cost-effectiveness analysis requires a value to be assumed for a clinically important outcome. This value is, however, uncertain. Eighth, the comparison here was between one type of drug therapy, with or without the addition of CBT. Pharmacological alternatives to mebeverine are available, and these include the 5HT 3 and 5HT 4 serotonergic agents. The evidence surrounding these is promising [28] , but they are not currently available in the UK. In the future, it would be helpful to compare the costeffectiveness of CBT with these interventions. Ninth, we relied on point estimates of symptoms at each follow-up assessment to generate change scores. An alternative method would have been to use area under the curve analysis. This, however, would have been more difficult to interpret in an economic evaluation. Tenth, the study compared two active treatments (drug therapy and drug therapy in addition to CBT), and did not include a placebo group. Given that the effectiveness of CBT was unknown, it would have been problematic to withhold existing treatment from patients. It should, however, be recognized that (i) some patients would have improved in the absence of any treatment and (ii) some who improved in the CBT in addition to mebeverine group might have done so because of nonspecific factors, rather than because of the addition of CBT per se. Finally, the CBT intervention probably differs from CBT elsewhere. A manual was used to assist patients, and this is not a standard CBT component. It could be argued that the intervention here contains elements of behavioural selfmanagement, and that other CBT interventions might well be more cost-effective.
To conclude, we can see that combined CBT and mebeverine treatment was most cost-effective in the short term. If society values a clinically important reduction in the symptoms of IBS at up to £250, then combined treatment is more cost-effective than drug therapy alone in the short term.
